Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.43 |
| ▸ | LPL | P06858 | 6/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 6/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274473 | 1.00 | LIPG (0.43) | LIPGLPLTRPV1MGLLPDK2 | |
| SCHEMBL3194907 | 1.00 | LIPG (0.43) | LIPGLPLTRPV1MGLLPDK2 | |
| SCHEMBL30800031 | 1.00 | LIPG (0.43) | LIPGLPLTRPV1MGLLPDK2 | |
| SCHEMBL3789775 | 1.00 | LIPG (0.43) | LIPGLPLTRPV1MGLLPDK2 | |
| SCHEMBL5502877 | 0.99 | LIPG (0.42) | LIPGLPLTRPV1MGLLPDK2 | |
| SCHEMBL5501674 | 0.95 | LIPG (0.40) | LIPGLPLTRPV1MGLLPDK2 | |
| SCHEMBL21125194 | 0.95 | LIPG (0.40) | LIPGLPLTRPV1MGLLPDK2 | |
| SCHEMBL16872804 | 0.94 | LIPG (0.40) | LIPGLPLTRPV1MGLLPDK2 | |
| SCHEMBL28537539 | 0.93 | LIPG (0.46) | LIPGLPLTRPV1MGLLPDK2 | |
| SCHEMBL374243 | 0.93 | LIPG (0.46) | LIPGLPLTRPV1MGLLPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921915-B2 | Metal coordination compound, luminescence device and display apparatus | CANON KABUSHIKI KAISHA (JP) | 2005-07-26 | — | — | US | disclosed |
| EP-1238981-B1 | Metal coordination compound, luminescence device and display apparatus | CANON KK (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20030068535-A1 | Metal coordination compound, luminescence device and display apparatus | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2003-04-10 | — | — | US | disclosed |
| EP-1238981-A2 | Metal coordination compound, luminescence device and display apparatus | CANON KABUSHIKI KAISHA (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030068535-A1 | Metal coordination compound, luminescence device and display apparatus | CCNL2, CYC1, CYCS | LIPG 1842/4885LPL 465/4885TRPV1 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.